Topics

Statistics

Infectious diseases Research 4 November 2024 Open Access

Factors associated with general practitioner‐led diagnosis of long COVID: an observational study using electronic general practice data from Victoria and New South Wales, Australia

Identification of predisposing risk factors is essential to inform early intervention and management strategies for patients at greatest risk of long COVID

Abbish Kamalakkannan · Mirela Prgomet · Judith Thomas · Christopher Pearce · Precious McGuire · Fiona Mackintosh · Andrew Georgiou

Statistics Perspective 7 October 2024 Open Access

Implementability and impact in clinical research and the role of clinical trial networks

A framework for planning, design and reporting of clinical trials, to optimise implementability

Helena J Teede · Karen Best · Frank H Bloomfield · Alan Cass · Paul Cohen · Sue Crengle · Tiffany Harris‐Brown · Stephen Jan · David W Johnson · Samantha Keogh · Anne McKenzie · Philippa Middleton · Sandra Peake · Hashim Periyalil · Paul A Scuffham · Angela Scheppokat · Greg R Sharplin · Steve Webb

Mja2 52444
Statistics Research 7 October 2024 Open Access

Holistic support framework for doctors training as rural and remote general practitioners: a realist evaluation of the RVTS model

Understanding how to deliver holistic supervision and support for the challenges doctors face when training as general practitioners in rural, remote and First Nations communities, can support interventions which build personal and professional resilience for rural practice

Belinda G O'Sullivan · Patrick Giddings · Ronda Gurney · Matthew R McGrail · Tiana Gurney

General medicine Research 7 October 2024 Open Access

Perceived stakeholder benefits of continuously training general practitioners in the same rural or remote practice: interviews exploring the Remote Vocational Training Scheme

The RVTS model of training doctors continuously in the same practice improves access to safe and high quality longitudinal care and contributes to service enhancements in rural, remote and First Nations communities that otherwise lack stable doctors

Belinda G O'Sullivan · Patrick Giddings · Matthew R McGrail

Women's health Guideline summary 23 September 2024 Open Access

Summary of the 2023 international evidence‐based guideline for the assessment and management of polycystic ovary syndrome: an Australian perspective

The 2023 International evidence-based guideline for the assessment and management of polycystic ovary syndrome provides updated evidence-based recommendations for the clinical assessment and management of polycystic ovary syndrome

Helena J Teede · Aya Mousa · Chau T Tay · Michael F Costello · Leah Brennan · Robert J Norman · Alexia S Pena · Jacqueline A Boyle · Anju Joham · Lorna Berry · Lisa Moran

Mja2 52432
Women's health Guideline summary 16 September 2024 Open Access

Recommendations from the 2024 Australian evidence‐based guideline for unexplained infertility: ADAPTE process from the ESHRE evidence‐based guideline on unexplained infertility

If we are to offer accessible, equitable, cost-effective fertility services to people who desire a child, we need to align to best practice evidence

For the Australian NHMRC Centre for Research Excellence in Reproductive Life UI Guideline Network and the ESHRE guideline group for unexplained infertility

Mja2 52437
Statistics Research 9 September 2024 Open Access

Policies on the collection, analysis, and reporting of sex and gender in Australian health and medical research: a mixed methods study

Research policy and guidelines for integrating sex and gender into health and medical research must be implemented and evaluated to achieve change

Cheryl Carcel · Amy Vassallo · Laura Hallam · Janani Shanthosh · Kelly Thompson · Lily Halliday · Jacek Anderst · Anthony KJ Smith · Briar L McKenzie · Christy E Newman · Keziah Bennett‐Brook · Zoe Wainer · Mark Woodward · Robyn Norton · Louise Chappell

Mja2 52435

The Alfred Health post‐COVID‐19 service, Melbourne, 2020–2022: an observational cohort study

To the Editor: Holland and colleagues reported on the Alfred Health post‐COVID‐19 service experience with the health of patients who had previously been hospitalised, or managed in a hospital‐in‐the‐home setting, with COVID‐19.1 Participants responded to an invitation to register for follow‐up, and then completed a questionnaire. The study also included a separate group (13% of the cohort) who were not necessarily admitted to Alfred Health but lived in the Alfred Health catchment — and might have been managed as outpatients or inpatients in another service but were referred by their local doctors to a specialist clinic targeted for patients with symptoms after initial COVID‐19, and subsequently completed the questionnaire. Sixty per cent of respondents had at least one persistent symptom at eight weeks. The study reported apparently high prevalences of other symptoms, such as post‐traumatic stress disorder in 23%. These results are derived from their cohort and may not be generally applicable. The authors caution: “We could not distinguish between new symptoms and those attributable to other health conditions. Our study did not include a contemporary control group”.1 More importantly, there was no control group of patients hospitalised from non‐COVID‐19 viral illness (with sufficient severe illness to lead to almost 5% spending time in an intensive care unit), who were then concentrated by an invitation, and then sufficiently motivated to fill out a questionnaire. Plausibly in such a group, at eight weeks, 60% would report at least one persistent symptom. Interpretation of their results is also obscured by the patients referred from the community, who came from a bigger population of patients with COVID‐19 concentrated to include only those who sought or agreed to a referral to a specialist follow‐up clinic. The authors wisely identified weaknesses and they should be applauded for their review of their experience. More definitive conclusions about higher rates of persisting ill health caused by COVID‐19 (in comparison to similarly severe infectious illness) might be achieved if they can follow this up — as they perhaps recognise — with a prospective analytic design in a cohort of patients presenting with similar severity of viral illness comparing those with and without COVID‐19 over the long term.

Jeremy L Millar

Pharmacology Perspective 29 July 2024 Open Access

National pharmacovigilance of seasonal influenza vaccines in Australia

Australia’s national pharmacovigilance systems work collaboratively to monitor the safety of seasonal influenza vaccines, with improvements to these systems ensuring the continued safety of medicines and vaccines available on the Australian market

Megan O'Moore · Belinda Jones · Megan Hickie · Catherine Glover · Lucy Deng · Yuanfei Huang · Michael Dymock · Evelyn Tay · Julie A Marsh · Nicholas Wood

Mja2 52381

Living evidence syntheses: the emerging opportunity to increase evidence‐informed health policy in Australia

Living evidence syntheses are critical for evidence-informed policy; however, their use is not as straightforward as providing policy makers with summarised results from research studies

Samantha P Chakraborty · Alex Collie · Rebecca Hodder · Suman S Majumdar · Kim Sutherland · Bernie Towler · Joshua Vogel · Andrew Wilson · Luke Wolfenden · Sally Green · Tari Turner

Mja2 52368

Subscribe to MJA email alerts

No spam, you can unsubscribe anytime you want.

By providing your information, you agree to our Terms of Use and our Privacy Policy.

Thanks for Subscribing! Tell us more

Your email updates will use your name.

Good one! Your updates are coming

Thank you for subscribing to the MJA email alerts. Receive the latest content in your inbox.